Pfizer is pushing into the crowded GLP-1 weight-loss market with an unusual pitch: a shot patients would need only once a month instead of once a week. New Phase 2b data the company released describe placebo-adjusted weight loss of up to 12.3% with its investigational candidate PF-08653944, previously known in earlier development as MET-097i.
What Pfizer Announced
The trial, part of Pfizer's VESPER program, tested PF-08653944 in adults with obesity or overweight and at least one weight-related condition. After a titration phase of up to 12 weeks, participants moved to a monthly maintenance dose. By week 28, the highest-dose group had lost an average of 12.3% more body weight than the placebo group, with weight loss still trending downward and no clear plateau at that point in the study.
How It's Different From Weekly GLP-1 Drugs
Every GLP-1 receptor agonist approved or in late-stage development for obesity today, including semaglutide (Wegovy) and tirzepatide (Zepbound), is dosed weekly. Pfizer designed PF-08653944 as what it describes as a fully-biased, ultra-long-acting GLP-1 receptor agonist, engineered to remain active in the body long enough to support once-monthly injections after the initial dose-finding period. If that interval holds up in larger trials, it would mean a meaningfully different treatment burden than anything currently on the market.
Safety Signals
The safety profile reported so far looks broadly similar to other drugs in this class: gastrointestinal side effects, mostly nausea and vomiting, were the most common adverse events and were generally described as mild to moderate. Severe gastrointestinal side effects were rare, occurring in no more than one case per dose group, and no participant reported severe diarrhea. Ten participants across the active treatment arms discontinued the trial due to side effects, compared with none in the placebo group.
Regulatory Status
PF-08653944 is an investigational drug. It has not been approved by the FDA for any use, and Phase 2b results, however promising, are not evidence of long-term safety or effectiveness in a broader population. Pfizer has said it plans to advance a 9.6 mg monthly dose into Phase 3 testing, the stage where regulators look for the kind of large-scale, longer-duration data needed to support an approval decision.
Part of a Broader Push Toward Less-Frequent Dosing
Pfizer isn't alone in exploring longer dosing intervals. Amgen's obesity candidate MariTide is also being developed as a monthly injection, and Viking Therapeutics has released maintenance-phase data suggesting its VK2735 candidate can preserve prior weight loss on an every-other-week schedule. Together, these programs suggest the next phase of competition in obesity drug development may focus as much on dosing convenience and durability as on peak weight-loss percentages alone.
What Happens Next
Phase 3 obesity trials typically enroll thousands of participants and run for a year or more, specifically to capture durability of weight loss, longer-term safety, and performance across a broader range of patients. Until those trials read out, it isn't possible to know whether the 12.3% placebo-adjusted weight loss seen in this Phase 2b population will hold up, or whether monthly dosing will prove as convenient and effective in practice as it looks on paper.
The Bottom Line
Pfizer's data add another entrant to an increasingly crowded pipeline of next-generation obesity drugs competing with Novo Nordisk and Eli Lilly's established products. The monthly-dosing angle is a genuine point of differentiation, but PF-08653944 remains years from a potential approval, and Phase 2b numbers are best read as encouraging early evidence rather than a settled result.